Current therapies for systemic lupus erythematosus (SLE), a debilitating, potentially lethal,
multifactorial systemic autoimmune disease, are limited to suppressing disease activity and …

Significant advances in the understanding of the molecular basis of innate immunity have
led to the identification of interferons (IFNs), particularly IFN-α, as central mediators in the …

Systemic lupus erythematosus (SLE) is a complex autoimmune disease with systemic
clinical manifestations including, but not limited to, rash, inflammatory arthritis, serositis …

Systemic lupus erythematosus (SLE) is a prototypic autoimmune disease characterized by
impaired immune tolerance, resulting in the generation of pathogenic autoantibodies and …

Type I and type III interferons (IFNs) share several properties in common, including the
induction of signaling pathways, the activation of gene transcripts, and immune responses …

Systemic lupus erythematosus (SLE) is a chronic, multisystem disorder characterised by loss
of tolerance to endogenous nuclear antigens and autoantibody formation. Recent insight …

The development of new medicines for systemic lupus erythematosus (SLE) has not
addressed unmet clinical need, with only three drugs receiving regulatory approval for SLE …

In recent years, the study of systemic lupus erythematosus (SLE) patients has revealed a
central role for type I interferon (IFN) in disease pathogenesis. IFN induces the unabated …

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease of unknown aetiology
that can be debilitating and life threatening. As new insights are gained into the underlying …

Clinical trials of investigational agents in systemic lupus erythematosus (SLE) have focused
on targeting dysregulated B and T cells; however, recent translational research findings of …